The Italian Multicentre Registry of Fenestrated Anaconda™ Endografts for Complex Abdominal Aortic Aneurysms Repair.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 22 08 2019
revised: 17 03 2020
accepted: 22 04 2020
pubmed: 28 7 2020
medline: 22 9 2020
entrez: 26 7 2020
Statut: ppublish

Résumé

The aim was to describe the outcomes of the Anaconda™ Fenestrated endograft Italian Registry for complex aortic aneurysms (AAAs), unsuitable for standard endovascular aneurysm repair (EVAR). Between 2012 and 2018 patients with a proximal neck unsuitable for standard EVAR, treated with the fenestrated Anaconda™ endograft, were prospectively enrolled in a dedicated database. Endpoints were peri-operative technical success (TS) and evaluation of type Ia/b or 3 endoleaks (T1/3 EL), target visceral vessel (TVV) occlusion, re-interventions, and AAA related mortality at 30 days, six months, and later follow up. One hundred twenty seven patients (74 ± 7 years, American Society Anesthesiology (ASA) II/III/IV: 12/85/30) were included in the study in 49 Italian Vascular Surgery Units (83 juxta/para-renal AAA, 13 type IV thoraco-abdominal AAA, 16 T1aEL post EVAR, and 15 short neck AAA). Configurations with one, two, three, and four fenestrations were used in 5, 56, 39, and 27 cases, respectively, for a total of 342 visceral vessels. One hundred and eight (85%) bifurcated and 19 (15%) tube endografts were implanted. In 35% (44/127) of cases the endograft was repositioned during the procedure, and 37% (128/342) of TVV were cannulated from brachial access. TS was 87% (111/127): five T1EL, six T3EL (between fenestration and vessel stent), and six loss of visceral vessels (one patient with a Type Ia EL had also a TVV loss) occurred. Thirty day mortality was 4% (5/127). Two of the five T1EL resolved spontaneously at 30 days. The overall median follow up was 21 ± 16 months; one T1EL (5%) occurred at six months and one T3EL (4%) at the three year follow up. Another two (3%) TVV occlusions occurred at six months and five (3%) at three years. The re-intervention rate at the 30 days, six months, and three year follow up was 5%, 7%, and 18 ± 5%, respectively. The fenestrated Anaconda™ endograft is effective in the treatment of complex AAA. Some structure properties, such as the re-positionability and the possibility of cannulation from above, are specific characteristics helpful for the treatment of some complex anatomies.

Identifiants

pubmed: 32709467
pii: S1078-5884(20)30372-5
doi: 10.1016/j.ejvs.2020.04.032
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-191

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Rodolfo Pini (R)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Policlinico Sant'Orsola-Malpighi, Bologna, Italy. Electronic address: rudypini@gmail.com.

Jacopo Giordano (J)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Policlinico Sant'Orsola-Malpighi, Bologna, Italy.

Michelangelo Ferri (M)

Dipartimento Strutturale Chirurgico, Ospedale Mauriziano, Turin, Italy.

Bruno Palmieri (B)

Dipartimento Cardiotoracovascolare, Ospedale Niguarda, Milan, Italy.

Marco Solcia (M)

Dipartimento Cardiotoracovascolare, Ospedale Niguarda, Milan, Italy.

Stefano Michelagnoli (S)

Dipartimento Chirurgico, Ospedale San Giovanni di Dio, Florence, Italy.

Emiliano Chisci (E)

Dipartimento Chirurgico, Ospedale San Giovanni di Dio, Florence, Italy.

Franco Fadda Gian (F)

Ospedale San Francesco, Nuoro, Italy.

Pierluigi Cappiello (P)

Ospedale San Carlo, Potenza, Italy.

Francesco Talarico (F)

Ospedale Civico, Palermo, Italy.

Silvio Licata (S)

Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.

Paolo Frigatti (P)

Dipartimento di Chirurgia Generale, Ospedale Santa Maria della Misericordia, Udine, Italy.

Sonia Ronchey (S)

Dipartimento delle Specialità Chirurgiche, Azienda Ospedaliera San Filippo Neri, Rome, Italy.

Nicola Mangialardi (N)

Dipartimento delle Specialità Chirurgiche, Azienda Ospedaliera San Filippo Neri, Rome, Italy.

Carlo Pratesi (C)

Dipartimento di Medicina Sperimentale e Clinica, Ospedale Careggi, Florence, Italy.

Mauro Salvini (M)

Dipartimento Chirurgico, Ospedale Civile, Alessandria, Italy.

Domenico Milite (D)

Dipartimento Strutturale Area Chirurgia Maggiore, Ospedale San Bortolo, Vicenza, Italy.

Fabio Pilon (F)

Dipartimento Strutturale Area Chirurgia Maggiore, Ospedale San Bortolo, Vicenza, Italy.

Reinhold Perkmann (R)

Ospedale di Bolzano, Bolzano, Italy.

Carlo Stringari (C)

Ospedale di Bolzano, Bolzano, Italy.

Raffaele Pulli (R)

Dipartimento dell'Emergenza e dei Trapianti di Organi, Policlinico di Bari, Bari, Italy.

Gianluca Faggioli (G)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Policlinico Sant'Orsola-Malpighi, Bologna, Italy.

Mauro Gargiulo (M)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Policlinico Sant'Orsola-Malpighi, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH